What is the catalog number for MTIC?

The catalog number for MTIC is HY-119696.

What sizes are available for MTIC?

MTIC is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does MTIC come in?

MTIC is available in 6 different pack sizes.

MTIC is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures MTIC?

MTIC is manufactured by QuantiMol.

What is the estimated delivery time for MTIC?

Estimated delivery time for MTIC is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for MTIC?

The safety data sheet for MTIC is available here: http://file.medchemexpress.com/batch_PDF/HY-119696/MTIC-SDS-MedChemExpress.pdf.

MTIC

MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity [1][2][3][4].

Product Specifications

CAS Number

3413-72-7

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mtic.html

Purity

99.51

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(/N=N/NC)N=CN1)N

Molecular Formula

C5H8N6O

Molecular Weight

168.16

Precautions

H302, H315, H319, H335

References & Citations

[1]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163. |[2]Nagasawa HT, et al. The mechanism of alkylation of DNA by 5- (3-methyl-1-triazeno) imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388) . Non-involvement of diazomethane. Chem Biol Interact. 1974 Jun;8 (6) :403-13.|[3]Tsang LL, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl- (triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27 (5) :342-6.|[4]Beal DD, et al. Carcinogenicity of the antineoplastic agent, 5- (3,3-dimethyl-1-triazeno) -imidazole-4-carboxamide, and its metabolites in rats. J Natl Cancer Inst. 1975 Apr;54 (4) :951-7.